Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Among authors: vickerman p. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.
Arif A, Hasnain A, Chaudhry A, Asim M, Shafqat MN, Altaf A, Saba N, Kemos P, Ansari MA, Barnes E, Metcalfe C, Vickerman P, Qureshi H, Hamid S, Choudhry AA, Niaz SK, Foster GR, Choudhry N. Arif A, et al. Among authors: vickerman p. BMC Public Health. 2023 Dec 18;23(1):2529. doi: 10.1186/s12889-023-17290-3. BMC Public Health. 2023. PMID: 38110885 Free PMC article.
Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination.
Shih STF, Stone J, Martin NK, Hajarizadeh B, Cunningham EB, Kwon JA, McGrath C, Grant L, Grebely J, Dore GJ, Lloyd AR, Vickerman P, Chambers GM. Shih STF, et al. Among authors: vickerman p. Open Forum Infect Dis. 2023 Dec 18;11(2):ofad637. doi: 10.1093/ofid/ofad637. eCollection 2024 Feb. Open Forum Infect Dis. 2023. PMID: 38344130 Free PMC article.
Vaccination coverage among people who inject drugs: A systematic review.
Price O, Swanton R, Grebely J, Hajarizadeh B, Webb P, Peacock A, Dore GJ, Cowie BC, Vickerman P, Degenhardt L. Price O, et al. Among authors: vickerman p. Int J Drug Policy. 2024 Mar 18;127:104382. doi: 10.1016/j.drugpo.2024.104382. Online ahead of print. Int J Drug Policy. 2024. PMID: 38503233 Free article. Review.
Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis.
Levinsson A, Zolopa C, Vakili F, Udhesister S, Kronfli N, Maheu-Giroux M, Bruneau J, Valerio H, Bajis S, Read P, Martró E, Boucher L, Morris L, Grebely J, Artenie A, Stone J, Vickerman P, Larney S. Levinsson A, et al. Among authors: vickerman p. EClinicalMedicine. 2024 Apr 10;72:102596. doi: 10.1016/j.eclinm.2024.102596. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38633576 Free PMC article.
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA; INTRO-HCV Study Group. Fadnes LT, et al. Among authors: vickerman p. BMC Infect Dis. 2019 Nov 8;19(1):943. doi: 10.1186/s12879-019-4598-7. BMC Infect Dis. 2019. PMID: 31703669 Free PMC article. Clinical Trial.
Peer involvement and cross-sector efforts in establishing integrated treatment of hepatitis C virus infection for people with substance use disorders: experiences from Norway.
Lygren OJ, Bjørnestad R, Løberg EM, Bonnier ML, Buljovcic VB, Johansson KA, Fadnes LT; INTRO-HCV Study Group. Lygren OJ, et al. Subst Abuse Treat Prev Policy. 2019 Dec 21;14(1):58. doi: 10.1186/s13011-019-0245-y. Subst Abuse Treat Prev Policy. 2019. PMID: 31864396 Free PMC article.
Kentucky Outreach Service Kiosk (KyOSK) Study protocol: a community-level, controlled quasi-experimental, type 1 hybrid effectiveness study to assess implementation, effectiveness and cost-effectiveness of a community-tailored harm reduction kiosk on HIV, HCV and overdose risk in rural Appalachia.
Young AM, Havens JR, Cooper HLF, Fallin-Bennett A, Fanucchi L, Freeman PR, Knudsen H, Livingston MD, McCollister KE, Stone J, Vickerman P, Freeman E, Jahangir T, Larimore E, White CR, Cheatom C, Community Staff K, Design Team K. Young AM, et al. Among authors: vickerman p. BMJ Open. 2024 Mar 1;14(3):e083983. doi: 10.1136/bmjopen-2024-083983. BMJ Open. 2024. PMID: 38431295 Free PMC article. Clinical Trial.
386 results